Migard frovatriptan: Phase IV; marketed

In a double-blind, crossover U.S. Phase IV study in 500 patients, 52% of patients in the 5 mg frovatriptan group were headache-free and 41% of the 2.5 mg frovatriptan group were headache-free compared...